Prognostic value of liquid biopsy in patients with rectal cancer treated with neoadjuvant chemotherapy
Project/Area Number |
16K10556
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Digestive surgery
|
Research Institution | Nippon Medical School |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
山田 岳史 日本医科大学, 医学部, 准教授 (50307948)
内田 英二 日本医科大学, 大学院医学研究科, 大学院教授 (70176684)
|
Project Period (FY) |
2016-04-01 – 2019-03-31
|
Project Status |
Completed (Fiscal Year 2018)
|
Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Keywords | 直腸癌 / 術前化学療法 / リキッドバイオプシー / バイオマーカー / 効果予測 / cell free DNA / 効果予測因子 / liquid biopsy / 癌 / 外科 / 遺伝子 / 臨床 |
Outline of Final Research Achievements |
Neoadjuvant chemotherapy (NAC) using FOLFOX regimen was given to 32 cases of rectal cancer patients. Three-year recurrence-free survival rates for responders (57%) and non-responders (47%) were 96% and 76% (p = 0.006), respectively. Circulating cell free DNA (ccf DNA) derived from cancer cells is reflected in the long fragment / short fragment ratio (DNA integrity: DI) of ccf DNA. The changing rate of DI before NAC and after NAC is 20% or more was 91% in responders and 20% in non-responders (p = 0.013). DI change rate reflects histologic response and could be a prognostic marker.
|
Academic Significance and Societal Importance of the Research Achievements |
直腸癌治療の中心は手術であるが、手術のみでは治療の限界があり、成績向上のためには化学療法の併用が期待されている。NACは忍容性の高い治療ストラテジーであるが、無効例が存在することが問題である。NAC開始から早期のうちに無効例を抽出することができれば、NACによる不利益を受ける症例を減らすことができる。またこれらの症例を他の治療法に振り分けることが、直腸癌全体のさらなる予後改善に繋がる可能性がある。 さらに、ccfDNAをバイオマーカーとした化学療法の効果予測法は直腸癌のみならず、他の癌腫の化学療法効果予測にも応用が期待できる。
|
Report
(4 results)
Research Products
(18 results)
-
-
-
-
-
[Presentation] Distal intramural spread of rectal cancer following neoadjuvant chemotherapy without radiotherapy2018
Author(s)
Koizumi M, Yamada T, Shinji S, Yokoyama Y, Takahashi G, Hotta M, Takeda K, Iwai T, Hara K, Ueda K, Takeda K, ,Ohta K, Yoshida H.
Organizer
14th European Society of Coloproctology
Related Report
Int'l Joint Research
-
-
-
-
-
-
-
-
-
[Presentation] The prognostic value of pathological response in rectal cancer patients receiving neoadjuvant FOLFOX2017
Author(s)
Michihiro Koizumi, Takeshi Yamada, Seiichi Shinji, Yasuyuki Yokoyama, Goro Takahashi, Masahiro Hotta, Takuma Iwai, Keisuke Hara, Kohki Takeda, Keiichiro Oota, Eiji Uchida
Organizer
European Society of Coloproctology
Related Report
Int'l Joint Research
-
-
-
-